Lakewood-Amedex Biotherapeutics Announces 1-for-10 Reverse Stock Split

What Happened Lakewood-Amedex Biotherapeutics Inc. filed an 8-K disclosing a 1-for-10 reverse stock split of its common stock. The Company filed a Certificate of Change with the Nevada Secretary of State on June 15, 2026; the reverse split becomes effective at 4:01 p.m. ET on June 19, 2026, and Lakewood-Amedex’s common stock will trade on a split-adjusted basis on Nasdaq when the market opens June 22, 2026. The Board unanimously approved the reverse split on June 1, 2026. The filing does not state a reason for the reverse split.

Key Details

• Reverse split ratio: 1-for-10; every ten existing shares will be exchanged for one post-split share. Fractional shares will be rounded up to the next whole share.
• Outstanding shares: will be reduced from approximately 17,506,577 shares pre-split to approximately 1,750,789 shares post-split.
• Authorized shares: concurrent proportionate reduction to leave 12,500,000 authorized shares of common stock after the split.
• Adjustments: conversion and exercise prices and the number of shares issuable under equity awards, preferred stock, warrants and incentive plans will be adjusted in accordance with their terms.
• Trading and ID: Common stock will continue trading on The Nasdaq Capital Market under the symbol “LABT”; a new CUSIP has been assigned (51255A201).

Why It Matters A reverse stock split changes the number of shares outstanding and typically increases the per‑share price without changing an owner’s proportional stake (aside from rounding). For investors, this affects share count, per‑share pricing, ticker mechanics (new CUSIP), and the share counts/prices for options, warrants and convertible securities. The filing contains no earnings, management changes, or other corporate actions beyond the reverse split and the Certificate of Change.